2,4-diisopropylquinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2,4-diisopropylquinazoline
• 英文别名: 2,4-Di(propan-2-yl)quinazoline
• 化学式: C₁₄H₁₈N₂
• 分子量: 214.31
• InChiKey: ZAJTVBXFFUCNKW-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.43
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  异丁腈 、 苯胺 在 tetrafluoroboric acid 、 sodium nitrite 作用下， 以 水 为溶剂， 反应 3.5h， 以46 mg的产率得到2,4-diisopropylquinazoline
  参考文献：
  名称：

  通过芳基重氮盐和腈的2 + 2 + 2环化制备喹唑啉

  摘要：

  通过芳基重氮盐与两个当量腈的直接反应，实现了多取代喹唑啉的（2 + 2 + 2）模块化合成。芳基重氮盐与腈的反应提供了反应性腈离子的初始形成，该离子被另一种腈分子攻击，随后进行亲电环化以提供所需的产物。该方法的优点是取代模式具有显着的灵活性，易于获得的底物，反应时间短，无过渡金属和克级合成。

  DOI：

  10.1021/acs.joc.7b01325

文献信息

• [EN] HETEROCYCLIC COMPOUNDS AND USE THEREOF<br/>[FR] COMPOSÉS HÉTÉROCYCLIQUES ET UTILISATION DE CES COMPOSÉS
  申请人：NATIONAL HEALTH RES INST

  公开号：WO2018132326A1

  公开（公告）日：2018-07-19

  Heterocyclic compounds of Formula (I) shown herein. Also disclosed is a pharmaceutical composition containing one of the heterocyclic compounds. Further disclosed are methods of using one of the heterocyclic compounds for mobilizing hematopoietic stem cells and endothelial progenitor cells into the peripheral circulation, and for treating tissue injury, cancer, inflammatory disease, and autoimmune disease.

  本文所示的式(I)的杂环化合物。还公开了含有其中一种杂环化合物的药物组合物。进一步公开了使用其中一种杂环化合物将造血干细胞和内皮祖细胞转移到外周循环，并用于治疗组织损伤、癌症、炎症性疾病和自身免疫疾病的方法。
• Dioxygen-Mediated Decarbonylative CH Alkylation of Heteroaromatic Bases with Aldehydes
  作者：Subhasis Paul、Joyram Guin

  DOI：10.1002/chem.201503809

  日期：2015.12.1

  An operationally simple and economical method for the direct alkylation of heteroaromatic bases employing readily available aldehydes as alkyl radical precursors and molecular oxygen as a reagent is presented. This simple transformation demonstrates a broad substrate scope with respect to aldehydes and nitrogen heterocycles, enabling the introduction of several medicinally important yet challenging

  提出了一种操作简单且经济的方法，用于将杂芳族碱直接烷基化，该方法使用容易获得的醛作为烷基前体，并使用分子氧作为试剂。这种简单的转化展示了针对醛和氮杂环的广泛底物范围，从而能够将几种具有医学重要性但极具挑战性的烷基部分（例如乙基，异丙基，叔丁基和环己基）引入到不同类别的杂环碱中，优异的产量。
• AMINO-ETHYL-AMINO-ARYL (AEAA) COMPOUNDS AND THEIR USE
  申请人：Raynham Tony Michael

  公开号：US20090247519A1

  公开（公告）日：2009-10-01

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain amino-ethyl-amino-aryl (AEAA) compounds which, inter alia, inhibit protein kinase D (PKD) (e.g., PKD1, PKD2, PKD3). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit PKD, and in the treatment of diseases and conditions that are mediated by PKD, that are ameliorated by the inhibition of PKD, etc., including proliferative conditions such as cancer, etc.

  本发明一般涉及治疗化合物领域，更具体地涉及某些氨基乙基氨基芳基（AEAA）化合物，该化合物在抑制蛋白激酶D（PKD）（例如，PKD1、PKD2、PKD3）方面起作用。本发明还涉及包含这些化合物的药物组合物，以及在体外和体内使用这些化合物和组合物来抑制PKD，并用于治疗由PKD介导的疾病和症状，通过抑制PKD而改善的疾病和症状等，包括增殖性疾病如癌症等。
• KINASE INHIBITOR SCAFFOLDS AND METHODS FOR THEIR PREPARATION
  申请人：Ding Sheng

  公开号：US20070191380A1

  公开（公告）日：2007-08-16

  General methods for the solution phase as well as solid phase synthesis of various substituted heteroaryls has been demonstrated. These substituted heteroaryls can be further elaborated by aromatic substitution with amines at elevated temperature or by anilines, boronic acids and phenols via palladium catalyzed cross-coupling reactions.

  展示了各种取代杂环芳基化合物的溶液相和固相合成的一般方法。这些取代杂环芳基化合物可以通过在高温下与胺进行芳香取代，或通过钯催化的交叉偶联反应与苯胺、硼酸和酚进一步精细化合成。
• Therapeutic Oxy-Phenyl-Aryl Compounds and Their Use
  申请人：Collins Ian

  公开号：US20110201592A1

  公开（公告）日：2011-08-18

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain oxy phenyl aryl compounds (referred to herein as OPA compounds), as described herein, which, inter alia, inhibit Checkpoint Kinase 2 (CHK2) kinase function. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit CHK2 kinase function, and in the treatment of diseases and conditions that are mediated by CHK2, that are ameliorated by the inhibition of CHK2 kinase function, etc., including proliferative conditions such as cancer, etc., optionally in combination with another agent, for example, (a) a DNA topoisomerase I or II inhibitor; (b) a DNA damaging agent; (c) an antimetabolite or TS inhibitor; (d) a microtubule targeted agent; and (e) ionising radiation.

  本发明涉及治疗化合物领域，更具体地涉及某些氧苯基芳基化合物（以下简称OPA化合物），如本文所述，该化合物在其中抑制检查点激酶2（CHK2）激酶功能。本发明还涉及包含这种化合物的制药组合物，以及在体外和体内使用这种化合物和组合物来抑制CHK2激酶功能，并治疗由CHK2介导，通过抑制CHK2激酶功能改善的疾病和病况，包括增殖性疾病，如癌症等，可选择与另一种药物一起使用，例如（a）DNA拓扑异构酶I或II抑制剂；（b）DNA损伤剂；（c）抗代谢物或TS抑制剂；（d）微管靶向药物；和（e）电离辐射。